The Indianapolis-based health insurer said the name change will better reflect its mission of “elevating whole health and advancing health beyond healthcare.”
Health care firm that runs clinics for employers is expanding nationwide
Marathon Health, which splits its headquarters between Indianapolis and suburban Burlington, Vermont, operates primary-care clinics for employers in 42 states.Read More
Donor organization to recover transplant organs at its own facility
The Indiana Donor Network Organ and Tissue Recovery Center has re-tasked two operating rooms and an intensive care unit to recover major organs, such as the kidneys, heart and lungs.Read More
As injuries mount, Methodist Sports Medicine expands to meet need
Founded in 1983, the practice has 28 physicians and annual revenue of $35 million, and shows little sign of slowing.Read More
Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.Read More
Two former employees of Anthem Inc. claim the Indianapolis-based health insurer set work quotas so high that it was impossible to meet them in a 40-hour week, forcing them to work unpaid overtime. Anthem declined to comment.
The companies say they can quickly develop new omicron-targeting antibodies, but those aren’t expected to launch for at least several months.
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
Indianapolis-based Apria announced its earnings Tuesday after the markets closed. It marked the company’s first earnings announcement since going public last month.
The aggressive offensive by a Russian-speaking criminal gang coincides with the U.S. presidential election, though there was no immediate indication it was motivated by anything but profit.
Renaissance Electronic Services, an Indianapolis-based tech company that announced major growth plans in 2016, has been acquired by Atlanta-based Vyne, the companies announced Thursday.
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs.
The new venture, called MBX Biosciences Inc., aims to develop therapeutics to treat rare endocrine disorders. The company has already raised $2.5 million in funding.
The drug rebate rule would have ended a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare. The idea was to channel that money to consumers instead.
Lilly shares dropped 4.6 percent in early trading after the company said Christi Shaw was leaving and Mike Harrington planned to retire.
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
It’s the second approved use for Emgality, which first won U.S. approval last fall to treat migraines. Analysts predict it could become a blockbuster.
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.